Holen Sie sich die Stockscreener-App
1.19
4.80%
-0.06
Handel nachbörslich:
1.18
-0.01
-0.84%
Clearmind Medicine Inc Aktie (CMND) Neueste Nachrichten
Clearmind gets safety board approval to continue AUD trial - Investing.com Nigeria
Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval - Bitget
Clearmind (Nasdaq: CMND) moves CMND-100 alcohol-use trial into higher-dose stage - Stock Titan
Clearmind Medicine IncDSMB approves continuation of Phase I/IIa CMND-100 trial in AUD - marketscreener.com
Alcohol use disorder drug from Clearmind moves to higher-dose testing - Stock Titan
CMND Earnings History & Surprises | EPS & Revenue Results | CLEARMIND MEDICINE INC (NASDAQ:CMND) - ChartMill
CMND Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
What is Clearmind Medicine Inc.’s book value per shareAnalyst Downgrade & Stepwise Trade Signal Guides - mfd.ru
Is Clearmind Medicine Inc. stock trending bullishAnalyst Downgrade & Precise Entry and Exit Recommendations - mfd.ru
Moonage Media Review: Clearmind's MEAI and GLP-1Are These the Next-Generation Treatment for Weight Loss? - lelezard.com
Market Rankings: How do insiders feel about Clearmind Medicine IncWeekly Stock Report & Growth Focused Entry Reports - baoquankhu1.vn
Clearmind Medicine (CMND) trims second tranche of convertible note deal - Stock Titan
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
What technical signals suggest for Clearmind Medicine Inc. stockJuly 2025 Intraday Action & Real-Time Volume Trigger Notifications - mfd.ru
How Clearmind Medicine Inc. (CWY0) stock trades pre earnings2025 Dividend Review & Expert Curated Trade Ideas - mfd.ru
Is Clearmind Medicine Inc. a turnaround storyWeekly Profit Analysis & Weekly Top Performers Watchlists - mfd.ru
Clearmind reports positive safety data from AUD treatment trial By Investing.com - Investing.com Australia
Clearmind reports positive safety results in AUD drug trial - Investing.com South Africa
Clearmind reports positive safety data from AUD treatment trial - Investing.com South Africa
Clearmind reports positive safety results in AUD drug trial By Investing.com - Investing.com Nigeria
Clearmind Medicine announces additional topline positive safety results reinforcing favorable profile of cmnd-100 in ongoing Phase I/Iia clinical trial - marketscreener.com
Clearmind Medicine stock falls after Phase I/IIa trial safety update By Investing.com - Investing.com South Africa
Clearmind Medicine stock falls after Phase I/IIa trial safety update - Investing.com Nigeria
Clearmind Medicine Announces Additional Positive Safety Topline Data From CMND-100 Study - Nasdaq
Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial - The Manila Times
Clearmind Medicine Inc. Reports Positive Safety Results from Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder - Quiver Quantitative
Polyrizon to develop intranasal formulation of Clearmind’s MEAI drug By Investing.com - Investing.com Nigeria
Clearmind partners with Polyrizon to develop intranasal MEAI formulation By Investing.com - Investing.com Nigeria
Clearmind Medicine (CMND) Stock: Partners With Polyrizon to Advance Intranasal MEAI Therapy - parameter.io
Polyrizon climbs on Clearmind Deal - Baystreet.ca
Polyrizon to develop intranasal formulation of Clearmind’s MEAI drug - Investing.com
Clearmind Medicine stock surges after Polyrizon intranasal delivery deal By Investing.com - Investing.com Nigeria
Clearmind partners with Polyrizon to develop intranasal MEAI formulation - Investing.com
Clearmind Medicine stock surges after Polyrizon intranasal delivery deal - Investing.com India
Clearmind Medicine enters development agreement for intranasal formulation of proprietary nonhallucinogenic neuroplastogen MEAI - marketscreener.com
Polyrizon and Clearmind Partner on Intranasal Non-Hallucinogenic Neuroplastogen MEAI - TipRanks
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation - The Manila Times
Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI - The Manila Times
Clearmind Medicine Inc. Partners with Polyrizon Ltd. to Develop Innovative Intranasal Formulation for MEAI in CNS Disorders - Quiver Quantitative
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic ... - Caledonian Record
Biotechs team up on intranasal, non-hallucinogenic addiction therapy - Stock Titan
Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments - The Manila Times
Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ ... - Caledonian Record
Breakouts Watch: Is Clearmind Medicine Inc a strong growth stock - baoquankhu1.vn
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):